Alexion Pharmaceuticals (NASDAQ:[[ticker:ALXN]]) reports it will pay $25 million to PDL BioPharma (NASDAQ:[[ticker:PDLI]]) to license a patent related to humanizing antibodies and to settle a legal dispute between the two companies. Cheshire, CT-based Alexion says the license enables the firm to commercialize its humanized antibody eculizumab (Soliris)—now approved to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria in the U.S. and Europe—for any use without threat of legal action by PDL BioPharma.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
